Tags : ORAL Shift

Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV

Tuba Khan June 13, 2019

Shots: The P-IIIB/IV study results involve assessing of Xeljanz XR (11 mg, qd) as monothx. followed by MTX withdrawal vs Xeljanz XR + MTX in 530 patients in ratio (1:1) […]readmore

Tags : ORAL Shift

Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ORAL Shift

﻿Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV